<DOC>
	<DOCNO>NCT01154153</DOCNO>
	<brief_summary>The primary objective evaluate effect 6-week treatment TAA-AQ ( 110 μg ) TAA-AQ ( 220 μg ) daily ( QD ) versus placebo hypothalamic-pituitary-adrenal ( HPA ) axis function measure serum cortisol AUC ( 0-24 hr ) child ( &gt; =2 &lt; 12 year old ) allergic rhinitis ( AR ) .</brief_summary>
	<brief_title>Nasacort AQ Hypothalamic-Pituitary-Adrenal ( HPA ) Axis Study Children With Allergic Rhinitis</brief_title>
	<detailed_description>The study consist run-in single-blind screening phase ( prerandomization ) follow approximately 6-week double-blind treatment phase ( postrandomization ) . Total study duration per participant last 7.5 13 week consist : - Screening single-blind phase ( 2 phase run concurrently , prerandomization ) 8 24 day . During screen phase participant give single-blind placebo nasal spray enable practice intranasal application technique daily morning ( 1 actuation/nostril ) . - Randomization double-blind treatment phase . Treatment assignment randomize stratification sex age group ( &gt; =2 &lt; 6 , &gt; =6 &lt; 12 year old ) . - Double-blind treatment phase last least 42 day run 47 day . Participants administer either TAA-AQ nasal spray placebo nasal spray . - An evaluation end treatment 1-3 day completion double-blind phase .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<criteria>Participants meet follow criterion eligible study : History AR document investigator , follow : At least 1year clinical history ( 6month history participant &gt; = 2 &lt; 4 year age ) perennial allergic rhinitis ( PAR ) ; clinical history seasonal allergic rhinitis ( SAR ) 2 season positive skin test ( prick intradermal ) seasonal perennial allergen present participant 's environment time screen . Written inform consent ability parent/legal guardian participant give write informed consent study related procedure . Participants &gt; =7 year age ( young accord govern institutional review board [ IRB ] ) provide sign assent form Concomitant medical condition might interfere administration nasal spray , include anatomical abnormality nose , face ( eg , polyposis , markedly deviate septum ) Presence active , untreated , clinically significant musculoskeletal , endocrinologic , gastrointestinal , hepatic , respiratory , cardiovascular , neurological condition might interfere study Any condition treatment might affect HPA axis plasma cortisol assay , include limited : Documented disorder involve hypothalamus , pituitary , adrenal gland Current use serotonergic , dopaminergic , adrenergic , cholinergic agonist antagonist , opiate , immunomodulatory , hormonal drug , lipidlowering agent Treatment systemic corticosteroid ( oral , intravenous , intramuscular , intraarticular ) within 3 month prior Visit 1 Treatment systemic corticosteroid &gt; 2 course receive 1 year Visit 1 exclusionary . Up 2 course systemic corticosteroid , course exceed 14 day , 1 year Visit 1 allow Treatment inhale , intranasal , highpotency topical corticosteroid within 6 week Visit 1 History hospitalization due asthma within 1 year screening . Participants mild asthma wellcontrolled without use inhaled corticosteroid within 6 week prior Visit 1 eligible study Any clinically significant ( determined investigator ) abnormal laboratory test Visit 1 Morning serum cortisol outside reference range Visit 1 Any follow miss serum cortisol sample Visit2 collection : first sample ( administration investigational product ) , 20hour sample , 24hour sample , 2 consecutive sample Any medical condition use corticosteroid might contraindicate could lead disease exacerbation ( eg , glaucoma , cataract , ocular herpes simplex , tuberculosis , growth retardation ) History hypersensitivity corticosteroid rescue medication , investigational product , excipients Unresolved upper respiratory tract infection , sinus infection , nasal candidiasis ( ie , symptomatic treatment ) within last 2 week prior Visit 1 Visit 3 Females childbearing potential protected effective contraceptive method birth control unwilling abstain sexual activity and/or , unwilling unable test pregnancy . Only female adolescent onset menses check serum pregnancy test Visit 1 Pregnant female adolescent ( test positive pregnancy Visit 1 ) The information intend contain consideration relevant potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>